Evidence map›Paper›PMID 34224375›Full record

ArticleCancer research2021

Carolina J Garcia Garcia, Joseph Abi Jaoude, Cullen M Taniguchi

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Carolina J Garcia Garcia *The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8330-1746
Joseph Abi Jaoude *The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cullen M TaniguchiThe University of Texas MD Anderson Cancer Center, Houston, Texas. ctaniguchi@mdanderson.org.ORCID 0000-0002-8052-3316
The University of Texas MD Anderson Cancer Center · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCsR01DE028529 · NIDCR · WASHINGTON UNIVERSITY · PI SANA D KARAM · 2019 to 2026
$3.7M
Role of EphB4-ephrin-B2 interaction in regulating crosstalk between cancer cell and vascular tumor microenvironment in head and neck cancerR01DE028282 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2019 to 2023
$2.4M
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosisR01HL147059 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDOFF, BENJAMIN DAVID · 2019 to 2023
$2.1M
NCI NIH HHS P30 CA046934NHLBI NIH HHS R01 HL147059NIDCR NIH HHS R01 DE028282NIDCR NIH HHS R01 DE028529
6 · The paper itself

Abstract

Radiotherapy plays an important role in the management of pancreatic ductal adenocarcinoma (PDAC), especially when patients are not surgical candidates. Radiation-induced tumor death provokes an acute inflammation followed by a late-fibrotic response that parallels the fibroinflammatory tumor microenvironment of PDAC, inciting the question of whether radiation-induced fibrosis contributes to PDAC progression. The study published in this issue by Mueller and colleagues presents a potential mechanism linking radiation-induced fibrosis with expression of a disintegrin and metalloprotease 10 (ADAM10) and ephrinB2, which may also contribute to tumor progression. The authors show that ablation of ADAM10 decreases radiation-induced fibrosis and improves survival in preclinical models. These data suggest that targeting ADAM10 may help to improve clinical outcomes with radiotherapy, particularly if definitive radiation is not possible. A better understanding of the biology of radiotherapy in pancreatic cancer remains crucial, and Mueller and colleagues offer important insight in this regard.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsADAM10 ProteinAmyloid Precursor Protein SecretasesEphrin-B2HumansMembrane ProteinsTumor MicroenvironmentADAM10 ProteinADAM10 protein, humanAmyloid Precursor Protein SecretasesEphrin-B2Membrane Proteins

Identifiers

PMID34224375
OpenAlexW3168409725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.